Journal article icon

Journal article

Gβγ subunit activation of K V 7 and BK Ca channels underlies calcitonin gene‐related peptide vasorelaxation in myogenic rat coronary resistance arteries

Abstract:
Background and Purpose: CGRP is a potent, clinically relevant coronary vasodilator known to play a role in cardioprotection. Here, we investigated the precise intracellular signalling pathways leading to vasodilation in small coronary arteries. Experimental Approach: This study used ex vivo myography and intracellular recording techniques to investigate α‐CGRP‐induced vasorelaxation and vascular smooth muscle cell (VSMC) hyperpolarization in myogenically active rat isolated coronary arteries. Key Results: CGRP‐induced vasorelaxation was not dependent on the endothelium, but relied heavily on K+ channel activation. Immunohistochemistry indicated KV7 and BKCa channel expression in VSMC and endothelial cells. A combination of the KV7 channel inhibitor, linopirdine and the BKCa channel inhibitor, paxilline, significantly attenuated CGRP‐induced vasorelaxation in endothelium‐intact or denuded arteries. Electrophysiology confirmed that CGRP caused hyperpolarization and showed this was prevented by linopirdine and paxilline, also demonstrating a role for KV7 and BKCa channels in suppressing depolarizing smooth muscle spikes. These spikes were also suppressed by NO• and HNO donors, resulting in hyperpolarization. Gβγ subunit inhibition with gallein markedly right‐shifted CGRP‐induced vasorelaxation in both endothelium‐intact and denuded coronary arteries. Conclusion and Implications: α‐CGRP stimulates robust vasorelaxation in the coronary microvasculature that relies on Gβγ subunit‐activated VSMC hyperpolarization involving KV7 and BKCa channels. These data enhance understanding of coronary microvascular physiology and inform the design of future therapeutic strategies targeting coronary vascular dysfunction.
Publication status:
Published
Peer review status:
Peer reviewed

Actions

Access Document

Files:
Publisher copy:
10.1111/bph.70492

Authors

More by this author
Institution:
University of Oxford
Role:
Author
ORCID:
0000-0002-8667-3032
More by this author
Institution:
University of Oxford
Role:
Author
ORCID:
0000-0001-6424-204X
More by this author
Institution:
University of Oxford
Role:
Author
More by this author
Institution:
University of Oxford
Role:
Author
ORCID:
0000-0003-0848-6044
More by this author
Institution:
University of Oxford
Role:
Author
ORCID:
0000-0002-8014-2775


More from this funder
Funder identifier:
https://ror.org/02wdwnk04
Grant:
FS/18/63/34184


Publisher:
Wiley
Journal:
British Journal of Pharmacology More from this journal
Article number:
bph.70492
Publication date:
2026-05-19
Acceptance date:
2026-04-15
DOI:
EISSN:
1476-5381
ISSN:
0007-1188


Language:
English
Keywords:
Source identifiers:
4061899
Deposit date:
2026-05-20
ARK identifier:
This ORA record was generated from metadata provided by an external service. It has not been edited by the ORA Team.

Terms of use


Views and Downloads






If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP